Empagliflozin is primarily used in the treatment of type 2 diabetes mellitus. It works by inhibiting the sodium-glucose co-transporter 2 (SGLT2) in the kidneys, which helps to lower blood glucose levels by promoting the excretion of excess glucose through urine. This mechanism of action is beneficial for patients who struggle to maintain glycemic control through diet, exercise, and other medications.

In addition to its glucose-lowering effects, empagliflozin has been shown to provide cardiovascular benefits. Clinical trials have demonstrated that it can reduce the risk of major adverse cardiovascular events, such as heart attack and stroke, in patients with type 2 diabetes who have established cardiovascular disease. This makes it a valuable option for patients with both diabetes and heart conditions.

Empagliflozin is also associated with weight loss and a reduction in blood pressure, which are additional advantages for patients managing type 2 diabetes. Its ability to improve glycemic control while offering these extra health benefits has made it a widely prescribed medication in the management of diabetes and related complications.